» Authors » Fabian D Mairinger

Fabian D Mairinger

Explore the profile of Fabian D Mairinger including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 27
Citations 257
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
21.
Mairinger F, Schmeller J, Borchert S, Wessolly M, Mairinger E, Kollmeier J, et al.
Oncotarget . 2018 Jun; 9(32):22254-22268. PMID: 29854276
Background: Malignant pleural mesothelioma (MPM) is a biologically highly aggressive tumor arising from the pleura with a dismal prognosis. Cisplatin is the drug of choice for the treatment of MPM,...
22.
Mairinger F, Walter R, Vollbrecht C, Hager T, Worm K, Ting S, et al.
Onco Targets Ther . 2014 Aug; 7:1441-7. PMID: 25152625
Background And Methods: Isothermal multiple displacement amplification (IMDA) can be a powerful tool in molecular routine diagnostics for homogeneous and sequence-independent whole-genome amplification of notably small tumor samples, eg, microcarcinomas...
23.
Mairinger F, Walter R, Werner R, Christoph D, Ting S, Vollbrecht C, et al.
J Cancer . 2014 Jun; 5(6):465-71. PMID: 24959299
Background: Lung cancer still remains the leading cause of cancer for men after prostate cancer and breast cancer for women. Angiogenesis is considered a major microenvironment modifier. Material And Methods:...
24.
Mairinger F, Walter R, Ting S, Vollbrecht C, Kollmeier J, Griff S, et al.
Future Oncol . 2014 Jun; 10(6):995-1005. PMID: 24941985
Aims: TP53 mutations are extremely rare in malignant pleural mesothelioma (MPM). In TP53 wild-type tumors, the functional p53 protein can be inactivated by MDM2. Materials & Methods: A total of...
25.
Walter R, Zarogoulidis P, Mairinger F, Werner R, Darwiche K, Zarogoulidis K, et al.
Int J Pharm . 2014 Mar; 466(1-2):38-43. PMID: 24607204
Background: Currently one of the major problems that interventional pulmonologists have to face is the increased proliferation of fibrinous tissue on the site of the stent placement, and usually at...
26.
Mairinger F, Vollbrecht C, Streubel A, Roth A, Landt O, Walter H, et al.
Appl Immunohistochem Mol Morphol . 2014 Feb; 22(2):114-8. PMID: 24517913
Background: Activating epidermal growth factor receptor (EGFR) gene mutations can be successfully treated by EGFR tyrosine kinase inhibitors (EGFR-TKIs), but nearly 50% of all patients' exhibit progression of the disease...
27.
Ting S, Mairinger F, Hager T, Welter S, Eberhardt W, Wohlschlaeger J, et al.
Clin Lung Cancer . 2013 Jul; 14(5):558-567.e3. PMID: 23810210
Introduction: Platinum-based chemotherapy is besides the standard antifolate therapy with pemetrexed, the cornerstone for treatment of patients with malignant pleural mesothelioma (MPM), and its efficacy depends on several DNA repair...